Eli Lilly's acquisition spree shows no sign of stalling, although the Big Pharma is keeping the terms of its latest buy ...
April 14 (Reuters) - The U.S. Food and Drug Administration has asked Eli Lilly for more data on liver injury linked to its ...
Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, an FDA document related to the oral treatment ...
With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 ...
The daily pill, called Foundayo, could make it easier for more people to lose weight.
The company could ride this tailwind through the medium term and deliver strong returns.
Worth up to $300 million, the buyout is Lilly’s latest of an ADC maker and adds technology for making “dual-payload” ...
On April 1, Eli Lilly (NYSE: LLY) and its shareholders received the news they were eagerly awaiting: the approval of the company's GLP-1 pill, Foundayo. While the company isn't the first out of the ...
Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug.
The U.S. Food and Drug Administration said Eli Lilly is required to conduct post-marketing trials to gauge risks for ...
Eli Lilly has rolled out Foundayo, its oral GLP-1 pill, directly to consumers through its LillyDirect cash-pay channel, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results